A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.

Trial Details

NCT ID
NCT07195682
Phase
PHASE1
Sponsor
Bristol-Myers Squibb
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • BMS-986506
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • New York, New York, United States|40.71427,-74.00597
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.
  • For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
  • For part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together …
  • Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →